Potentiation of motoneurone excitability by combined administration of 5-HT agonist and TRH analogue.
K A Clarke, A J Parker, G C Stirk
Neuropeptides June 1, 1985 DOI: 10.1016/0143-4179(85)90098-8 (opens in new tab) via PubMed
Summary
AI-generated from the abstractIn anesthetized rats, a combination of a thyrotropin-releasing hormone analogue (RX77368) and a serotonin receptor agonist (5MeODMT) produced a larger increase in the amplitude and duration of motoneuron field potentials in the lumbar spinal cord than either drug given alone. The findings suggest a potentiating interaction between the 5-HT and TRH systems in modulating spinal motoneuron excitability.
Study at a glance
| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Rats anaesthetised with urethane |
| Interventions | RX77368 5-methoxy-N N-dimethyl-tryptamine |
| Dose | 1mg/kg RX77368 plus 0.4mg/kg 5MeODMT |
| Citations | 39 |
| Key finding | Combined administration of RX77368 and 5MeODMT potentiated the increase in amplitude and duration of motoneurone field potentials compared to either drug alone. |
Abstract
Motoneurone field potentials have been recorded from the lumbar region of the spinal cord, to antidromic stimulation of a ventral root, in rats anaesthetised with urethane. Injection of the thyrotropin releasing hormone (TRH) analogue RX77368 (1mg/kg) plus the 5-hydroxytryptamine (5-HT) receptor agonist 5-methoxy-N, N-dimethyl-tryptamine (5MeODMT 0.4mg/kg) resulted in a potentiation of the increase in amplitude and duration of response, compared to when the drugs were given singly. These results are discussed in the context of possible interactions between 5-HT and TRH systems.